By Michael Dabaie

Eli Lilly & Co. said it is in a strategic research collaboration with Banner Alzheimer's Institute as part of the planned Phase 3 study evaluating donanemab in participants at risk for cognitive and functional decline related to Alzheimer's disease.

The TRAILBLAZER-ALZ 3 study will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer's disease in trial participants.

Starting in 2006, Banner Alzheimer's Institute seeks to find effective Alzheimer's disease prevention therapies.

Banner will support enrollment of trial participants through the Alzheimer's Prevention Registry's GeneMatch program, Eli Lilly said. The company and Banner will use the screening and treatment data as a shared scientific resource. Lilly said it remains the sole sponsor of the clinical trial and plans to begin enrollment later this year.

Donanemab is also being studied in the ongoing Phase 3 TRAILBLAZER-ALZ 2 study in early, symptomatic Alzheimer's disease patients.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

07-15-21 1041ET